Vyera said its bankruptcy was the result of declining profits, increased competition for generic drugs, and litigation alleging that Vyera suppressed competition for its most valuable drug, Daraprim.
Vyera filed a Chapter 11 plan in court on Wednesday, laying out it its intent to repay creditors through asset sales.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: